Anti-Von Willebrand Factor抗体- Aminoterminal end (ab47160)


  • 产品名称
    Anti-Von Willebrand Factor抗体- Aminoterminal end
    参阅全部 Von Willebrand Factor 一抗
  • 描述
    兔多克隆抗体to Von Willebrand Factor - Aminoterminal end
  • 特异性
    This antibody recognizes the 2,813 and 2,752 amino acid forms of Von Willebrand Factor, but only a portion of the 2,764 amino acid form.
  • 经测试应用
    适用于: WBmore details
  • 种属反应性
    与反应: Human
  • 免疫原

    Synthetic peptide based on the aminoterminal end of full length Human Von Willebrand Factor.



Our Abpromise guarantee covers the use of ab47160 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

应用 Ab评论 说明
  • 应用说明
    WB: 1/1000 - 1/5000. Predicted molecular weight: 309 kDa. A recommended starting concentration for Western blots is 1/1000 when using colorimetric substrates such as BCIP/NBT, and 1/5000 for chemiluminescent substrates. Notes: Many bands of varying sizes can be seen on Western blots, perhaps indicating differential processing by ADAMTS13 and other enzymes. Dilution optimised using Chromogenic detection. Not yet tested in other applications. Optimal dilutions/concentrations should be determined by the end user.
  • 靶标

    • 功能
      Important in the maintenance of hemostasis, it promotes adhesion of platelets to the sites of vascular injury by forming a molecular bridge between sub-endothelial collagen matrix and platelet-surface receptor complex GPIb-IX-V. Also acts as a chaperone for coagulation factor VIII, delivering it to the site of injury, stabilizing its heterodimeric structure and protecting it from premature clearance from plasma.
    • 组织特异性
    • 疾病相关
      Defects in VWF are the cause of von Willebrand disease (VWD) [MIM:277480]. VWD defines a group of hemorrhagic disorders in which the von Willebrand factor is either quantitatively or qualitatively abnormal resulting in altered platelet function. Symptoms vary depending on severity and disease type but may include prolonged bleeding time, deficiency of factor VIII and impaired platelet adhesion. Type I von Willebrand disease is the most common form and is characterized by partial quantitative plasmatic deficiency of an otherwise structurally and functionally normal Willebrand factor; type II is associated with a qualitative deficiency and functional anomalies of the Willebrand factor; type III is the most severe form and is characterized by total or near-total absence of Willebrand factor in the plasma and cellular compartments, also leading to a profound deficiency of plasmatic factor VIII.
    • 序列相似性
      Contains 1 CTCK (C-terminal cystine knot-like) domain.
      Contains 4 TIL (trypsin inhibitory-like) domains.
      Contains 3 VWFA domains.
      Contains 3 VWFC domains.
      Contains 4 VWFD domains.
    • 结构域
      The von Willebrand antigen 2 is required for multimerization of vWF and for its targeting to storage granules.
    • 翻译后修饰
      All cysteine residues are involved in intrachain or interchain disulfide bonds.
      N- and O-glycosylated.
    • 细胞定位
      Secreted. Secreted > extracellular space > extracellular matrix. Localized to storage granules.
    • Information by UniProt
    • 数据库链接
    • 别名
      • Coagulation factor VIII antibody
      • Coagulation factor VIII VWF antibody
      • F8VWF antibody
      • Factor VIII related antigen antibody
      • von Willebrand antigen 2 antibody
      • von Willebrand antigen II antibody
      • Von Willebrand disease antibody
      • VWD antibody
      • vWF antibody
      • VWF_HUMAN antibody
      see all

    Anti-Von Willebrand Factor antibody - Aminoterminal end 图像

    • All lanes : Anti-Von Willebrand Factor antibody - Aminoterminal end (ab47160) at 1/1000 dilution

      Lane 1 : Human serum reduced sample buffer at 1 µl
      Lane 2 : Human serum reduced sample buffer at 0.5 µl
      Lane 3 : Human serum reduced sample buffer at 0.25 µl

      Predicted band size : 309 kDa
      Observed band size : 170,302 kDa (why is the actual band size different from the predicted?)

    Anti-Von Willebrand Factor antibody - Aminoterminal end (ab47160)参考文献

    ab47160 has not yet been referenced specifically in any publications.

    Product Wall

    Vielen Dank für Ihren Anruf.

    Nachdem ich wie versprochen alle unsere Von Willebrand Faktor- Antikörperdaraufhin untersucht habe, ob sie möglicherweise die Bindung von Faktor VIII inhibieren können, weiß ich nicht, ob...

    Read More

    This one may not be as simple as the last, the only antibody I have found
    that we know recognizes the region the customer is targetting is ab47160.
    But on the datasheet, it says that it only recognizes the 5813 &2752 forms of vWF,

    Read More

    We have antibodies against CD34 and CD105 that are known to be reactive with the human CD antigens, but non-reactiivity with mouse CD antigens is more difficult to demonstrate consistently. We do not have any antibodies against these proteins (or other...

    Read More

    I just found the homology information for the immunogen for ab47160: It is 74% homolog with mouse. The antibody might not crossreact with mouse, but we cannot guarantee it as this has not yet been tested. I hope this is of help. Please let me know if y...

    Read More

    Thank you for contacting us. All 3 antibodies were raised against the human full length protein. I checked the homology with the mouse full length protein and it is 83%. Cross reactivity might therefore be likely, but has not been tested. Since we do n...

    Read More

    Thank you for your patience. I have gathered all the information for the vWF protein. As I mentioned in my recent email, the homology between human and mouse vWF full length proteins is 83%. Most of our antibodie have been raised against full lengt...

    Read More

    Thank you for calling Abcam earlier. I have heard back from the lab about ab47160, Anti-Von Willebrand Factor antibody - Aminoterminal end. They have told me that there is a 74% degree of homology between the immunogen sequence used to generate this an...

    Read More